Case Page

 

Case Status:    DISMISSED    
On or around 12/16/2008 (Stipulation and order of dismissal (voluntary dismissal))

Filing Date: March 13, 2008

The original complaint charges Vertex and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Vertex is a pharmaceutical company engaged in the discovery, development and commercialization of small molecule drugs for the treatment of serious diseases.

The complaint alleges that during the Class Period, defendants made false and misleading statements about the development of Vertex' s HCV protease inhibitor, telaprevir or VX-950, for the treatment of hepatitis C. Specifically, defendants made favorable statements regarding VX-950 but failed to disclose unfavorable data from a trial of the drug called PROVE 2. When the truth was disclosed on November 2, 2007, Vertex' s stock price dropped from $31.64 to $24.08 in two trading days.

According to the complaint, defendants' statements regarding VX-950 and the PROVE 2 trial were materially false and misleading because they failed to disclose unfavorable data regarding VX-950 from the PROVE 2 trial compared to PROVE 1. Specifically, PROVE 1 showed that patients taking VX-950 experienced 16% greater total viral reduction after twelve weeks compared to the control group. The results of PROVE 2, which defendants did not disclose during the Class Period, showed an advantage over the control group of only six percent.

On May 29, 2008, Judge Richard G. Stearns signed the Orders granting the motion to consolidate the cases and granting the motion to appoint the City of Fort Myers Police Officers' Retirement System as lead plaintiff and approving their selection of lead and liaison counsel. On July 21, 2008, the lead plaintiff filed an Amended Complaint. The defendants filed a motion to dismiss the Amended Complaint on September 25, 2008. On December 16, 2008, a Joint Stipulation of Voluntary Dismissal With Prejudice was filed and the civil action was terminated.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: VRTX
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Massachusetts
DOCKET #: 08-CV-10414
JUDGE: Hon. Leo T. Sorokin
DATE FILED: 03/13/2008
CLASS PERIOD START: 06/12/2007
CLASS PERIOD END: 11/02/2007
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Coughlin Stoia Geller Rudman & Robbins LLP (Melville)
    58 South Service Road, Suite 200, Coughlin Stoia Geller Rudman & Robbins LLP (Melville), NY 11747
    631.367.7100 631.367.1173 · info@csgrr.com/
  2. Shapiro Haber & Urmy LLP (Boston)
    53 State Street, Shapiro Haber & Urmy LLP (Boston), MA 02109
    617.439.3939 617.439.0134 · info@shulaw.com
No Document Title Filing Date
COURT: D. Massachusetts
DOCKET #: 08-CV-10414
JUDGE: Hon. Leo T. Sorokin
DATE FILED: 07/21/2008
CLASS PERIOD START: 06/12/2007
CLASS PERIOD END: 11/02/2007
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Coughlin Stoia Geller Rudman & Robbins LLP (Melville)
    58 South Service Road, Suite 200, Coughlin Stoia Geller Rudman & Robbins LLP (Melville), NY 11747
    631.367.7100 631.367.1173 · info@csgrr.com/
No Document Title Filing Date
No Document Title Filing Date